Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin

Br J Haematol. 2017 Dec;179(5):841-843. doi: 10.1111/bjh.14257. Epub 2016 Jul 22.

Authors

Matthew Howell^{1

2

3}, Adam Gibb^{1

2}, John Radford^{1

2

4}, Kim Linton^{1

2

4}

Affiliations

¹ Department of Medical Oncology, The Christie NHS Foundation Trust, Withington, Manchester, M20 4BX, UK.
² Manchester Academic Health Science Centre, The University of Manchester, Manchester, M13 9NT, UK.
³ Cancer Research UK Manchester Institute, Withington, Manchester, M20 4BX, UK.
⁴ Institute of Cancer Sciences, The University of Manchester, Manchester, M13 9PL, UK.

PMID: 27447404
DOI: 10.1111/bjh.14257

No abstract available

Keywords: Hodgkin lymphoma; allogeneic transplantation; bendamustine; brentuximab vedotin; refractory.

Publication types

Letter

MeSH terms

Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Agents, Alkylating / adverse effects
Antineoplastic Agents, Alkylating / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bendamustine Hydrochloride / administration & dosage
Bendamustine Hydrochloride / adverse effects
Bendamustine Hydrochloride / therapeutic use*
Brentuximab Vedotin
Drug Resistance, Neoplasm
Hematopoietic Stem Cell Transplantation* / methods
Hodgkin Disease / pathology*
Hodgkin Disease / therapy*
Humans
Immunoconjugates / therapeutic use
Recurrence
Retreatment
Transplantation, Homologous
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Immunoconjugates
Brentuximab Vedotin
Bendamustine Hydrochloride